Bio-Techne (TECH) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
- Market cap
- $11.4B
- As of Nov 5, 2026
- P/E
- 62.68x
- Latest fiscal year
- P/B
- 5.41x
- Latest reported equity
- P/S
- 9.39x
- Latest fiscal year
- ROE
- 8.6%
- Latest fiscal year
- Dividend yield
- 0.44%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $11.4B
- As of Nov 5, 2026
- P/E
- 62.68x
- Latest fiscal year
- P/B
- 5.41x
- Latest reported equity
- P/S
- 9.39x
- Latest fiscal year
- ROE
- 8.6%
- Latest fiscal year
- Dividend yield
- 0.44%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
62.68x
P/B
5.41x
P/S
9.39x
Earnings and dividend metrics▾
Earnings
EPS
$1.16
Earnings per share
BPS
$13.43
Book value per share
ROE
8.6%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.16 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $13.43 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 8.6%.
Dividends
Yield
0.44%
Dividend per share
$0.32
Payout ratio
27.5%
Consecutive years
1+ yrs
Yield uses fiscal 2026 dividends · Dividend per share and payout ratio are for fiscal 2026.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $32.00 before tax.
- Payout ratio — 27.5% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 1 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsApr–Jun 2026(FY2026 Q4)
Revenue increased 0.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
The fourth-quarter figure is the annual total minus the first three quarters.
Revenue · same quarter, three years
Year-ago quarter $318M+0.9%
Annual total minus the first three quarters (the filing does not report the fourth quarter on its own).
$306M
Apr–Jun '24
$318M
Apr–Jun '25
$321M
Apr–Jun '26
U.S. Eastern date
ⓘ Notes on these figures▾
- Results for Apr–Jun 2026 are from the 10-K submitted to SEC EDGAR on Aug 24, 2026.
- Revenue is the annual total minus the first three quarters; the filing does not report the fourth quarter on its own.
- Revenue increased 0.9% from the same quarter a year earlier.
- Operating income is the annual total minus the first three quarters; the filing does not report the fourth quarter on its own.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income is the annual total minus the first three quarters; the filing does not report the fourth quarter on its own.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- The next earnings report is scheduled for Nov 9, 2026 (U.S. Eastern).
Filed Aug 24, 2026 · 10-K · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Hippel JamesCFO · Nov 1, 2026Shares withheld for taxes5,096 shares · $370KAvg. price $72.66176,720 shares held after
- Kelderman KimChief Executive Officer · Nov 1, 2026Shares withheld for taxes2,385 shares · $173KAvg. price $72.6680,509 shares held after
- Hippel JamesCFO · Nov 1, 2026Option exercise11,545 shares · $0Avg. price $0181,816 shares held after
- Klimovsky Judith V.Director · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $06,532 shares held after
- Herr Amy E.Director · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $05,430 shares held after
- HIGGINS JOHN LDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $080,004 shares held after
- Bushman Julie LDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $011,525 shares held after
- BAUMGARTNER ROBERT VDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $059,634 shares held after
- KEEGAN JOSEPH DDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $018,161 shares held after
- Vessey RupertDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $013,737 shares held after
- Seth AlpnaDirector · Oct 29, 2026Grant or award2,750 shares · $0Avg. price $018,161 shares held after
- HIGGINS JOHN LDirector · Sep 28, 2026Shares withheld for taxes5,562 shares · $403KAvg. price $72.5177,254 shares held after
- HIGGINS JOHN LDirector · Sep 28, 2026Option exercise15,940 shares · $0Avg. price $082,816 shares held after
- BAUMGARTNER ROBERT VDirector · Sep 22, 2026Shares withheld for taxes5,559 shares · $403KAvg. price $72.5556,884 shares held after
- BAUMGARTNER ROBERT VDirector · Sep 22, 2026Option exercise15,940 shares · $0Avg. price $062,443 shares held after
- Kelderman KimChief Executive Officer · Aug 15, 2026Shares withheld for taxes21,776 shares · $1.6MAvg. price $72.4
Show 2 price lots
- 10,955 shares × $72.4$793K
- 10,821 shares × $72.4$783K
- Hippel JamesCFO · Aug 15, 2026Shares withheld for taxes8,733 shares · $632KAvg. price $72.4
Show 2 price lots
- 4,423 shares × $72.4$320K
- 4,310 shares × $72.4$312K
- Geist WilliamPRESIDENT, PROTEIN SCIENCES · Aug 15, 2026Shares withheld for taxes3,995 shares · $289KAvg. price $72.4
Show 2 price lots
- 2,019 shares × $72.4$146K
- 1,976 shares × $72.4$143K
- Crouse Steven C.President - Diag & Spatial Bi · Aug 15, 2026Shares withheld for taxes1,947 shares · $141KAvg. price $72.410,237 shares held after
- Bohnen ShaneSVP - General Counsel · Aug 15, 2026Shares withheld for taxes2,709 shares · $196KAvg. price $72.4
Show 2 price lots
- 1,366 shares × $72.4$99K
- 1,343 shares × $72.4$97K
- Herr Amy E.Director · Aug 15, 2026Shares withheld for taxes213 shares · $15KAvg. price $72.4576 shares held after
- Kelderman KimChief Executive Officer · Aug 15, 2026Option exercise43,206 shares · $0Avg. price $0
Show 2 price lots
- 21,736 shares × $0$0
- 21,470 shares × $0$0
- Bohnen ShaneSVP - General Counsel · Aug 15, 2026Option exercise8,770 shares · $0Avg. price $0
Show 2 price lots
- 4,420 shares × $0$0
- 4,350 shares × $0$0
- Hippel JamesCFO · Aug 15, 2026Option exercise19,759 shares · $0Avg. price $0
Show 2 price lots
- 9,980 shares × $0$0
- 9,779 shares × $0$0
- Herr Amy E.Director · Aug 15, 2026Option exercise589 shares · $0Avg. price $0789 shares held after
- Crouse Steven C.President - Diag & Spatial Bi · Aug 15, 2026Option exercise5,423 shares · $0Avg. price $012,184 shares held after
- Geist WilliamPRESIDENT, PROTEIN SCIENCES · Aug 15, 2026Option exercise12,963 shares · $0Avg. price $0
Show 2 price lots
- 6,416 shares × $0$0
- 6,547 shares × $0$0
- Hippel JamesCFO · Jul 29, 2026Shares withheld for taxes51,024 shares · $3.7MAvg. price $72.03164,714 shares held after
- Hippel JamesCFO · Jul 29, 2026Option exercise62,068 shares · $3.0MAvg. price $47.6215,738 shares held after
- Kelderman KimChief Executive Officer · Jul 28, 2026Shares withheld for taxes28,686 shares · $2.1MAvg. price $72.0772,113 shares held after
- Kelderman KimChief Executive Officer · Jul 28, 2026Option exercise35,000 shares · $1.7MAvg. price $47.6100,799 shares held after
- Bohnen ShaneSVP - General Counsel · Jul 23, 2026Shares withheld for taxes344 shares · $25KAvg. price $71.777,353 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KThe company said its Board of Directors decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2026. It said future cash dividends will be considered by the Board on a quarterly basis.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KBio-Techne said Dr. Matt McManus, President of its Diagnostics and Spatial Biology Segment, will transition from his role effective March 1, 2026 and will remain with the company for a period of time to support a smooth transition.Published Oct 3, 2026 · Filed Feb 11, 2026Read the summary →
- AI summary8-KThe company said second-quarter revenue for the quarter ended December 31, 2025 was $295.9 million, flat from the prior year on both a reported and organic basis. Its adjusted operating margin was 31.1%, compared with 30.1% a year earlier.Published Oct 5, 2026 · Filed Feb 4, 2026Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Bio-Techne (TECH) stock information
NASDAQ
Bio-Techne (TECH) is listed on NASDAQ. Its market capitalization is about $11.4B. On trailing-twelve-month earnings the P/E ratio is 62.68, and the P/B ratio is 5.41. Return on equity is 8.6%. These figures are computed in-house from official filings and are reference information only.
Bio-Techne — frequently asked questions
- What is the P/E ratio of Bio-Techne (TECH)?
- On a trailing-twelve-month basis, TECH trades at a P/E ratio of 62.68. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Bio-Techne?
- TECH has a market capitalization of about $11.4B. The figure moves with the share price and is refreshed each trading day.
- Does Bio-Techne pay a dividend?
- TECH has a dividend yield of about 0.44%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.